Baxter/Halozyme's HyQvia wins EU nod for immunodeficiencies

05/23/2013 | PharmaTimes (U.K.)

Baxter International and Halozyme Therapeutics obtained approval from the European Commission to market HyQvia as a replacement treatment for adults with primary and secondary immunodeficiency disorders. The treatment, a combination of human normal immunoglobulin and recombinant human hyaluronidase, is intended to be taken once every three to four weeks.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN